Viewing nowPregabalin Capsule 50 mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Medica Korea Co., Ltd.

MFDS item code 201904424 · Approved 2019.06.27 · Insurance code 646004810
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, applicable in cases with or without secondary general symptoms. Furthermore, it aids in alleviating symptoms of fibromyalgia. Its efficacy in treating various neurological disorders makes it beneficial for improving patients' pain and symptoms.
This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalinᵃ / Dosing regimen ≥60 / Initial dose 150 (mg/day), maximum dose 600 (mg/day) / BID or TID ≥30-<60 / Initial dose 75 (mg/day), maximum dose 300 (mg/day) / BID or TID ≥15-<30 / Initial dose 25-50 (mg/day), maximum dose 150 (mg/day) / QD or BID <15 / Initial dose 25 (mg/day), maximum dose 75 (mg/day) / QD Supplemental dose after hemodialysis / Initial dose 25, maximum dose 100 / Single doseᵇ TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: Supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if there are any changes in mood or behavior while taking it, patients should immediately consult a healthcare professional. Patients with allergies to any of the ingredients in this medication or with certain genetic disorders should not take it. Diabetic patients may need to adjust their blood sugar controlling medications due to potential weight gain. If symptoms of angioedema occur, use should be stopped immediately, and elderly patients should be cautious of accidents due to dizziness or drowsiness. Visual changes such as blurred vision may occur, and symptoms may improve after discontinuation of the medication. Discontinuing the drug suddenly may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be tapered off gradually in consultation with a healthcare professional. Patients with a history of substance abuse are at a higher risk of misuse of this medication, and should be particularly cautious while taking it. Patients with impaired renal function may require dose adjustments. Patients with heart disease should use this medication cautiously. When taken with other drugs that have central nervous system depressant effects, there is an increased risk of drowsiness or respiratory depression. Pregnant women should not take this medication in early pregnancy due to potential effects on the fetus, and women of childbearing age should use effective contraception. Lactating women should consider discontinuing breastfeeding or the medication, as it may be transferred into breast milk. Caution is advised when driving or operating machinery due to the risk of dizziness or drowsiness. In case of overdose, symptoms like confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be required if necessary. Keep this medication out of reach of children and ensure it is not transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain its efficacy by storing it at room temperature between 15°C and 30°C.
Hard capsule with upper dark blue and lower white part containing white or yellowish powder
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Medica Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.